Abstract: Platform trials gained popularity during the last few years as they increase flexibility compared to multi-arm trials by allowing new experimental arms entering when the trial already started. Using a shared control group in platform trials increases the trial efficiency compared to separate trials. Because of the later entry of some of the experimental treatment arms, the shared control group includes concurrent and non-concurrent control data. For a given experimental arm, non-concurrent controls refer to patients allocated to the control arm before the arm enters the trial, while concurrent controls refer to control patients that are randomised concurrently to the experimental arm. Using non-concurrent controls can result in bias in the estimate in case of time trends if the appropriate methodology is not used and the assumptions are not met. In this paper, we faced two main objectives. In the first, we aimed to identify the methods currently available for incorporating non-concurrent controls, clarify the key concepts and assumptions, and name the main characteristics of each method. For this purpose, we systematically searched research articles on methods to include non-concurrent controls. The second objective is to summarise the current regulatory view on non-concurrent controls to clarify the key concepts and current guidance. Therefore, we conducted a systematic search in regulatory guidelines regarding using non-concurrent controls and summarised the most relevant arguments and recommended methods. Finally, we discuss the advantages and potential caveats of using non-concurrent controls.